Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2361-2370

  Szczaurska Nowak, Katarzyna ^a   Da̧browska, Krystyna ^a   Celka, Marta ^a   Kurzȩpa, Aneta ^a   Nevozhay, Dmitry ^a   Wietrzyk, Joanna ^a   Świtała Jeleń, Kinga ^a   Syper, Danuta ^a   Poźniak, Gryzelda ^c   Opolski, Adam ^a,d   Górski, Andrzej ^a,b   Radzikowski, Czesław ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Anticancer activity; B16 melanoma; Bacteriophage T4 preparation (BP T4); Cancer; Melanoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; PROBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIOPHAGE T4; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SAFETY; LOW DRUG DOSE; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BACTERIOPHAGE T4; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; LIPOPOLYSACCHARIDES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 67650925041     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pennazio S: The origin of phage virology. Riv Biol 99: 103-129, 2006.
2. Fishetti VA, Nelson D and Schuch R: Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 24: 1508-1511, 2006.
3. Stone R: Stalin's forgotten cure. Science 298: 728-731, 2002.
4. Wang J, Hu B, Xu M, Yan O, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong J, Li QQ and Hu J: Therapeutic effectiveness of bacteriophages in the rescue of mice with extended-spectrum beta-lactamase producing Escherichia coli bacteremia. Int J Mol Med 17: 347-355, 2006.
5. Wang J, Hu B, Xu M, Yan O, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ and Hu J: Use of bacteriophage in the treatment of experimental bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17: 309-317, 2006.
6. Pirisi A: Phage therapy- advantages over antibiotics. Lancet 365: 1418, 2000.
7. Da̧browska K, Switala-Jelen K, Opolski A, Weber-Dabrowska B and Gorski A: Bacteriophage penetration in vertebrates. J Appl Microbiol 98: 7-13, 2005.
8. Górski A and Weber-Da̧browska B: The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62: 511-519, 2005. (Pubitemid 40386333)
9. Weber-Da̧browska B, Zimecki M and Mulczyk M: Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch Immunol Ther Exp 48: 31-37, 2000.
10. Weber-Da̧browska B, Zimecki M, Mulczyk M and Górski A: Effect of phage therapy on turnover and function of peripheral neutrophils. FEMS Immunol Med Microbiol 34: 135-138, 2002.
11. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S and Adhya S: Long-circulating bacteriophages as antibacterial agents. Microbiology 93: 3188-3192, 1996.
12. Nau R and Eiffert H: Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15: 95-110, 2002. (Pubitemid 34052584)
13. Daæbrowska K, Opolski A, Wietrzyk J, Świtała- Jeleń K, Boratyński J, Nasulewicz A, Lipińska L, Chybicka A, Kujawa M, Zabel M, Dolińska-Krajewska B, Piasecki E, Weber-Da̧browska B, Rybka J, Salwa J, Wojdat E, Nowaczyk M and Górski A: Antitumour activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of β3 integrin signalling pathway. Acta Virol 48: 241-248, 2004. (Pubitemid 47434295)
14. Da̧browska K, Opolski A, Wietrzyk J, Świtała- Jeleń K, Godlewska J, Boratyński J, Syper D, Weber- Da̧browska B and Górski A: Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 24: 3991-3995, 2004. (Pubitemid 40468698)
15. Da̧browska K, Opolski A, Wietrzyk J, Nevozhay D, Szczaurska K, Świtala-Jeleń K, Boratyński J and Górski A: Activity of bacteriophages in murine tumour models depends on the route of phage administration. Oncology Res 15: 183-187, 2005. (Pubitemid 41176503)
16. Fogelman I, Davey V, Ochs HD, Elashoff M, Feinberg MB, Mican J, Siegel JP, Sneller M and Lane HC: Evaluation of CD4+T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 182: 435-441, 2000.
17. Wilis AE, Perham RN and Wraith D: Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene 128: 79-83, 1993. (Pubitemid 23179213)
18. Gorski A, Dabrowska K, Switala-Jelen K, Nowaczyk M, Weber- Da̧browska B, Boratyński J, Wietrzyk J and Opolski A: New insights into the possible role of bacteriophages in host defense and disease. Med Immunol 2: 2, 2003. (Pubitemid 38751428)
19. Humphries MJ, Olden K and Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233: 467-470, 1986. (Pubitemid 16046307)
20. Kuphal S, Bauer R and Bosserhoff A-K: Integrin signaling in malignant melanoma. Cancer and Metastasis Rev 24: 195-222, 2005.
21. Świtała-Jeleń K, Da̧browska K, Opolski A, Lipińska L and Górski A: The biological functions of 3 integrins. Folia Biol (Praha) 50: 143-152, 2004.
22. Boratyński J, Syper D, Weber-Dabrowska B, Łusiak- Szelachowska M, Poźniak G and Górski A: Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9: 253-259, 2004.
23. Adams MH: Bacteriophages. New York, Inter Science Publ 1959.
24. Westphal OJ and Jann K: Bacterial lipopolisaccharides: extraction with phenol-water and further applications of the procedure. Meth Carbohydr Chem 5: 83-89, 1965.
25. Skehan P, Storeneg R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anti-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990. (Pubitemid 20213250)
26. de Jonge ME, Huitema AD, Rodenhuis S and Beijnen JH: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44: 1135-1164, 2005.
27. Eriksson F, Culp WD, Massey R, Egevad L, Garland D, Persson MA and Pisa P: Tumor specific phage particles promote tumor regression a mouse melanoma model. Cancer Immunol Immunother 56: 677-687, 2007. (Pubitemid 46348740)
28. - Inagawa H, Nishizawa T, Noguchi K, Minamimura M, Talagi K, Goto S, Soma G and Mizuno D: Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 17: 2153-2158, 1997. (Pubitemid 27320961)